JP2004519469A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004519469A5 JP2004519469A5 JP2002562339A JP2002562339A JP2004519469A5 JP 2004519469 A5 JP2004519469 A5 JP 2004519469A5 JP 2002562339 A JP2002562339 A JP 2002562339A JP 2002562339 A JP2002562339 A JP 2002562339A JP 2004519469 A5 JP2004519469 A5 JP 2004519469A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- thien
- hydroxy
- composition according
- benzo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 239000004480 active ingredient Substances 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 3
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 239000004202 carbamide Substances 0.000 claims 2
- 125000001589 carboacyl group Chemical group 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000000725 suspension Substances 0.000 claims 2
- NBLQZTAAMULKEF-UHFFFAOYSA-N 1-hydroxy-1-[1-(3-methyl-1-benzothiophen-2-yl)ethyl]urea Chemical compound C1=CC=C2C(C)=C(C(N(O)C(N)=O)C)SC2=C1 NBLQZTAAMULKEF-UHFFFAOYSA-N 0.000 claims 1
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 claims 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 101150065749 Churc1 gene Proteins 0.000 claims 1
- 241000021559 Dicerandra Species 0.000 claims 1
- 235000010654 Melissa officinalis Nutrition 0.000 claims 1
- 102100038239 Protein Churchill Human genes 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000008298 dragée Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000007938 effervescent tablet Substances 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 239000000865 liniment Substances 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- QHXPDZPAJHZYNT-UHFFFAOYSA-N n-[1-(1-benzothiophen-2-yl)ethyl]-n-hydroxyacetamide Chemical compound C1=CC=C2SC(C(N(O)C(C)=O)C)=CC2=C1 QHXPDZPAJHZYNT-UHFFFAOYSA-N 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 239000011505 plaster Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10103506A DE10103506A1 (de) | 2001-01-26 | 2001-01-26 | Pharmazeutische Zusammensetzung zur Behandlung von Multiple Sklerose |
| PCT/EP2002/000653 WO2002062332A1 (de) | 2001-01-26 | 2002-01-23 | Pharmazeutische zusammensetzung zur behandlung von multiple sklerose |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004519469A JP2004519469A (ja) | 2004-07-02 |
| JP2004519469A5 true JP2004519469A5 (enExample) | 2005-06-09 |
Family
ID=7671836
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002562339A Pending JP2004519469A (ja) | 2001-01-26 | 2002-01-23 | 多発性硬化症を処置するための医薬組成物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20050020665A1 (enExample) |
| EP (1) | EP1363618B1 (enExample) |
| JP (1) | JP2004519469A (enExample) |
| DE (2) | DE10103506A1 (enExample) |
| WO (1) | WO2002062332A1 (enExample) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014037832A2 (en) | 2012-09-06 | 2014-03-13 | Mahesh Kandula | Compositions and methods for the treatment of epilepsy and neurological diseases |
| WO2013167990A1 (en) | 2012-05-07 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of depression |
| CN104603096A (zh) | 2012-05-07 | 2015-05-06 | 塞利克斯比奥私人有限公司 | 用于治疗神经肌肉障碍和神经退行性疾病的组合物和方法 |
| JP2015519333A (ja) | 2012-05-07 | 2015-07-09 | セリックスビオ プライヴェート リミテッド | 神経疾患の治療のための組成物および方法 |
| US9266823B2 (en) | 2012-05-08 | 2016-02-23 | Cellix Bio Private Limited | Compositions and methods for the treatment of parkinson's disease |
| WO2013167992A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of inflammatory disorders |
| WO2013168025A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of blood clotting disorders |
| WO2013167991A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of metabolic disorders |
| US9434704B2 (en) | 2012-05-08 | 2016-09-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological degenerative disorders |
| WO2013168001A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
| WO2013168014A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of familial amyloid polyneuropathy |
| US9573927B2 (en) | 2012-05-10 | 2017-02-21 | Cellix Bio Private Limited | Compositions and methods for the treatment of severe pain |
| US9315478B2 (en) | 2012-05-10 | 2016-04-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
| WO2013168011A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of chronic pain |
| US9315461B2 (en) | 2012-05-10 | 2016-04-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurologic diseases |
| US9394288B2 (en) | 2012-05-10 | 2016-07-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of asthma and allergy |
| WO2013168033A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of neurologic diseases |
| US9339484B2 (en) | 2012-05-10 | 2016-05-17 | Cellix Bio Private Limited | Compositions and methods for the treatment of restless leg syndrome and fibromyalgia |
| US9403857B2 (en) | 2012-05-10 | 2016-08-02 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
| WO2013168002A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neurological conditions |
| US9242939B2 (en) | 2012-05-10 | 2016-01-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of respiratory disorders |
| US9346742B2 (en) | 2012-05-10 | 2016-05-24 | Cellix Bio Private Limited | Compositions and methods for the treatment of fibromyalgia pain |
| WO2013175376A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of local pain |
| JP2015518854A (ja) | 2012-05-23 | 2015-07-06 | セリックスビオ プライヴェート リミテッド | 多発性硬化症の治療のための組成物および方法 |
| EP2852571A4 (en) | 2012-05-23 | 2015-11-25 | Cellix Bio Private Ltd | COMPOSITIONS AND METHOD FOR THE TREATMENT OF MUCOSITIS |
| WO2013175344A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of periodontitis and rheumatoid arthritis |
| WO2013175347A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of respiratory disorders |
| JP6202287B2 (ja) | 2012-05-23 | 2017-09-27 | セリックスビオ プライヴェート リミテッド | 炎症性腸疾患の治療のための組成物及び方法 |
| US9108942B1 (en) | 2014-11-05 | 2015-08-18 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
| US9187427B2 (en) | 2012-08-03 | 2015-11-17 | Cellix Bio Private Limited | N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases |
| WO2014037833A2 (en) | 2012-09-06 | 2014-03-13 | Mahesh Kandula | Compositions and methods for the treatment inflammation and lipid disorders |
| US9670153B2 (en) | 2012-09-08 | 2017-06-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammation and lipid disorders |
| US9333187B1 (en) | 2013-05-15 | 2016-05-10 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory bowel disease |
| SG11201509782TA (en) | 2013-06-04 | 2015-12-30 | Cellix Bio Private Ltd | Compositions and methods for the treatment of diabetes and pre-diabetes |
| US9096537B1 (en) | 2014-12-31 | 2015-08-04 | Mahesh Kandula | Compositions and methods for the treatment of mucositis |
| NZ736131A (en) | 2014-09-26 | 2019-04-26 | Cellix Bio Private Ltd | Compositions and methods for the treatment of epilepsy and neurological disorders |
| JP6698643B2 (ja) | 2014-09-29 | 2020-05-27 | セリックス バイオ プライヴェート リミテッドＣｅｌｌｉｘ Ｂｉｏ Ｐｒｉｖａｔｅ Ｌｉｍｉｔｅｄ | 多発性硬化症の治療のための組成物及び方法 |
| EP3212626B1 (en) | 2014-10-27 | 2018-11-07 | Cellix Bio Private Limited | Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis |
| US9284287B1 (en) | 2014-11-05 | 2016-03-15 | Cellix Bio Private Limited | Compositions and methods for the suppression of carbonic anhydrase activity |
| US9321716B1 (en) | 2014-11-05 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
| US9150557B1 (en) | 2014-11-05 | 2015-10-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of hyperglycemia |
| US9290486B1 (en) | 2014-11-05 | 2016-03-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy |
| US9173877B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
| US10208014B2 (en) | 2014-11-05 | 2019-02-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological disorders |
| US9175008B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Prodrugs of anti-platelet agents |
| US9932294B2 (en) | 2014-12-01 | 2018-04-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
| US9206111B1 (en) | 2014-12-17 | 2015-12-08 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological diseases |
| EP3242869B1 (en) | 2015-01-06 | 2021-10-27 | Cellixbio Private Limited | Compositions and methods for the treatment of inflammation and pain |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4873259A (en) * | 1987-06-10 | 1989-10-10 | Abbott Laboratories | Indole, benzofuran, benzothiophene containing lipoxygenase inhibiting compounds |
| DE3882732T2 (de) * | 1987-02-10 | 1993-12-02 | Abbott Lab | Indol, Benzofuran, Benzothiophen enthaltende, Lipoxygenase hemmende Verbindungen. |
| US5093356A (en) * | 1990-01-16 | 1992-03-03 | Merck Frosst Canada, Inc. | Indenyl hydroxamic acids and hydroxy ureas as inhibitors of 5-lipoxygenase |
| DE69224115T2 (de) * | 1991-07-30 | 1998-08-20 | Ciba Geigy Ag | Heteroaryl substituierte Hydroxylaminderivate als Lipoxygenase-Inhibitoren |
| US6060501A (en) * | 1994-06-02 | 2000-05-09 | Schering Aktiengesellschaft | Combined treatment of multiple sclerosis |
| ITMI962356A1 (it) * | 1996-11-13 | 1998-05-13 | Uni Degli Studi Di Brescia D I | Uso di composti derivati da molecole ad attivita' antinfiammatoria di tipo non steroideo per la prevenzione e il trattamento di |
-
2001
- 2001-01-26 DE DE10103506A patent/DE10103506A1/de not_active Ceased
-
2002
- 2002-01-23 EP EP02719715A patent/EP1363618B1/de not_active Expired - Lifetime
- 2002-01-23 JP JP2002562339A patent/JP2004519469A/ja active Pending
- 2002-01-23 US US10/470,212 patent/US20050020665A1/en not_active Abandoned
- 2002-01-23 WO PCT/EP2002/000653 patent/WO2002062332A1/de not_active Ceased
- 2002-01-23 DE DE50206657T patent/DE50206657D1/de not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004519469A5 (enExample) | ||
| CN101801189B (zh) | 用于治疗沙粒病毒感染的抗病毒药 | |
| JP5380078B2 (ja) | アレナウイルス感染の治療のための抗ウイルス薬剤 | |
| JP2009538276A5 (enExample) | ||
| RU2008133654A (ru) | Способ и лекарственное средство для лечения тяжелой сердечной недостаточности | |
| JP2013508279A5 (enExample) | ||
| KR20160128305A (ko) | Hbv 감염의 치료를 위한 병용 요법 | |
| RU2006109467A (ru) | Способы лечения рака с использованием ингибиторов hdac | |
| EA200700049A1 (ru) | Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением | |
| JP2019515908A5 (enExample) | ||
| JP2011528713A5 (enExample) | ||
| WO2021147235A1 (zh) | 法匹拉韦在治疗冠状病毒感染方面的应用 | |
| JP2006503850A5 (enExample) | ||
| JP2019515884A5 (enExample) | ||
| JP2008503533A5 (enExample) | ||
| RU2009110452A (ru) | Галеновые составы алискирена | |
| JP2010540519A5 (enExample) | ||
| CA2671470A1 (en) | Powder formulation for valganciclovir | |
| EA020283B1 (ru) | Средство для профилактики и лечения высокопатогенных инфекционных заболеваний | |
| JP2005506298A5 (enExample) | ||
| SE9901573D0 (sv) | New compounds | |
| JP2008510758A5 (enExample) | ||
| JP2009521473A5 (enExample) | ||
| RU2008119454A (ru) | Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом | |
| RU2005133665A (ru) | Применение производных 10-гидрокси-10,11-дигидрокарбамазепина для лечения аффективных расстройств |